A detailed history of Amalgamated Bank transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,763 shares of RVNC stock, worth $7,100. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,763
Previous 2,763 -0.0%
Holding current value
$7,100
Previous $14,000 42.86%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$4.65 - $9.31 $41,840 - $83,771
-8,998 Reduced 76.51%
2,763 $14,000
Q4 2023

Feb 06, 2024

SELL
$5.81 - $11.2 $4,775 - $9,206
-822 Reduced 6.53%
11,761 $103,000
Q2 2023

Aug 11, 2023

BUY
$24.7 - $37.61 $28,923 - $44,041
1,171 Added 10.26%
12,583 $318,000
Q1 2023

May 02, 2023

SELL
$18.36 - $35.27 $35,508 - $68,212
-1,934 Reduced 14.49%
11,412 $368,000
Q4 2022

Feb 10, 2023

BUY
$18.32 - $30.66 $31,858 - $53,317
1,739 Added 14.98%
13,346 $246,000
Q3 2022

Nov 09, 2022

BUY
$14.33 - $28.47 $7,953 - $15,800
555 Added 5.02%
11,607 $313,000
Q2 2022

Aug 15, 2022

SELL
$11.52 - $20.4 $4,331 - $7,670
-376 Reduced 3.29%
11,052 $153,000
Q1 2022

Jun 30, 2022

SELL
$12.36 - $20.31 $11,445 - $18,807
-926 Reduced 7.5%
11,428 $223,000
Q4 2021

Feb 15, 2022

SELL
$12.46 - $27.87 $2,267 - $5,072
-182 Reduced 1.45%
12,354 $202,000
Q3 2021

Oct 29, 2021

SELL
$25.78 - $33.21 $18,535 - $23,877
-719 Reduced 5.42%
12,536 $349,000
Q2 2021

Aug 16, 2021

BUY
$26.8 - $31.84 $137,618 - $163,498
5,135 Added 63.24%
13,255 $393,000
Q1 2021

May 13, 2021

SELL
$24.03 - $29.97 $16,700 - $20,829
-695 Reduced 7.88%
8,120 $227,000
Q4 2020

Feb 12, 2021

BUY
$23.41 - $28.34 $912 - $1,105
39 Added 0.44%
8,815 $249,000
Q3 2020

Oct 30, 2020

BUY
$23.23 - $34.3 $203,866 - $301,016
8,776 New
8,776 $221,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.